

February 9, 2026

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001
Company Code No. AUROPHARMA	Company Code No. 524804

Dear Sir / Madam,

Sub: Proposal of merger of two wholly owned subsidiaries of the Company.

We would like to inform you that a proposal to file a Scheme of Amalgamation for merger of Auro Vaccines Private Limited, a wholly owned step-down subsidiary of the Company with Curateq Biologics Private Limited, a wholly owned subsidiary of the Company, with Hon'ble NCLT, Hyderabad, has been approved by the Board of Directors of the respective companies and also the Company.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, in this regard is attached as **Annexure**.

The Board meeting commenced at 4:30 p.m. and concluded at 6.30 p.m.

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Enclosures: as above.

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No.2, Maithrivihiar, Ameerpet, Hyderabad-500 038, Telangana, India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Annexure

Sl. No.	Particulars	Details						
a	Name of the entity(ies) forming part of the amalgamation/merger, details in brief such as, size, turnover etc.;	<p>Curateq Biologics Private Limited, a wholly owned subsidiary of the Company (Curateq) is the transferee company which was incorporated in India on April 25, 2020.</p> <p>Auro Vaccines Private Limited, a wholly owned step-down subsidiary of the Company (Auro Vaccines), is the transferor company which was incorporated in India on November 8, 2021. Auro Vaccines is a wholly owned subsidiary of Curateq.</p> <p>The turnover of Curateq and Auro Vaccines for the financial year ended March 31, 2025 is as under</p> <table border="1" data-bbox="794 819 1430 965"> <thead> <tr> <th>Name of the Company</th><th>Turnover for the FY ended March 31, 2025 (INR in million)</th></tr> </thead> <tbody> <tr> <td>Curateq</td><td>84.8</td></tr> <tr> <td>Auro Vaccines</td><td>Nil</td></tr> </tbody> </table>	Name of the Company	Turnover for the FY ended March 31, 2025 (INR in million)	Curateq	84.8	Auro Vaccines	Nil
Name of the Company	Turnover for the FY ended March 31, 2025 (INR in million)							
Curateq	84.8							
Auro Vaccines	Nil							
b	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”;	Yes, the transaction is between two wholly owned subsidiaries of the Company. As per the provisions of Section 188 of Companies Act, 2013 and Regulation 23(5)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, provisions relating to related party transactions are not applicable in respect of transactions among wholly owned subsidiaries of the Company.						
c	Area of business of the entity(ies);	Manufacturing and marketing pharmaceutical products.						
d	Rationale for amalgamation/ merger;	The consolidation of these entities will result in reducing the number of entities in the group, optimization of operational costs and reduction in regulatory compliances.						
e	In case of cash consideration – amount or otherwise share exchange ratio;	No consideration since the proposed merger is between two wholly owned subsidiaries of the Company.						
f	Brief details of change in shareholding pattern (if any) of listed entity.	<p>Not applicable.</p> <p>The Company is not a party to the Scheme of Amalgamation and the shareholding pattern of the Company remains unchanged.</p>						

AUROBINDO PHARMA LIMITED
www.aurobindo.com

(CIN : L24239TG1986PLC015190)

 Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
 Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

 Regd. off.: Plot No.2, Maithrivihiar, Ameerpet, Hyderabad-500 038, Telangana, India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
 Email: info@aurobindo.com Website: www.aurobindo.com